BR112018006138A2 - derivados de piridina fundidos como inibidores da cinase - Google Patents

derivados de piridina fundidos como inibidores da cinase

Info

Publication number
BR112018006138A2
BR112018006138A2 BR112018006138A BR112018006138A BR112018006138A2 BR 112018006138 A2 BR112018006138 A2 BR 112018006138A2 BR 112018006138 A BR112018006138 A BR 112018006138A BR 112018006138 A BR112018006138 A BR 112018006138A BR 112018006138 A2 BR112018006138 A2 BR 112018006138A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
pyridine derivatives
fused pyridine
kinase
pi4kiiiß
Prior art date
Application number
BR112018006138A
Other languages
English (en)
Inventor
Tracey Horsley Helen
Madden James
Thomas Reuberson James
Hugh Rowley Julian
Original Assignee
Katholieke Univ Leuven K U Leuven R&D
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven R&D, Ucb Biopharma Sprl filed Critical Katholieke Univ Leuven K U Leuven R&D
Publication of BR112018006138A2 publication Critical patent/BR112018006138A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

uma série de derivados de pirido[3,2-d]pirimidina e 1,5-naftiridina substituídos da fórmula (i), como aqui definidos, sendo inibidores seletivos da atividade de fosfatidilinositol-4-cinase iiiß (pi4kiiiß), são benéficos no tratamento e/ou prevenção de várias doenças humanas, incluindo distúrbios inflamatórios, autoimunes e oncológicos; doenças virais e malária; e rejeição ao transplante de órgão e célula.
BR112018006138A 2015-09-30 2016-09-28 derivados de piridina fundidos como inibidores da cinase BR112018006138A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1517264.6A GB201517264D0 (en) 2015-09-30 2015-09-30 Therapeutic agents
PCT/EP2016/073029 WO2017055306A1 (en) 2015-09-30 2016-09-28 Fused pyridine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112018006138A2 true BR112018006138A2 (pt) 2018-10-23

Family

ID=54544325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006138A BR112018006138A2 (pt) 2015-09-30 2016-09-28 derivados de piridina fundidos como inibidores da cinase

Country Status (9)

Country Link
US (1) US20180273525A1 (pt)
EP (1) EP3356365A1 (pt)
JP (1) JP2018529724A (pt)
CN (1) CN108137580A (pt)
BR (1) BR112018006138A2 (pt)
CA (1) CA2999929A1 (pt)
EA (1) EA201890826A1 (pt)
GB (1) GB201517264D0 (pt)
WO (1) WO2017055306A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939268A (en) * 1971-04-10 1976-02-17 Boehringer Ingelheim Gmbh 2,4-Diamino substituted pyridol(3,2-d)pyrimidine as antithrombotic agents
GB0503961D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
US20110257170A1 (en) * 2008-10-03 2011-10-20 Merck Serono Sa 4-morpholino-pyrido[3,2-d]pyrimidines
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
CA2804304C (en) * 2010-05-24 2020-02-25 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2014096423A1 (en) * 2012-12-20 2014-06-26 Ucb Pharma S.A. Therapeutically active pyrazolo-pyrimidine derivatives

Also Published As

Publication number Publication date
JP2018529724A (ja) 2018-10-11
GB201517264D0 (en) 2015-11-11
WO2017055306A1 (en) 2017-04-06
CN108137580A (zh) 2018-06-08
CA2999929A1 (en) 2017-04-06
EP3356365A1 (en) 2018-08-08
US20180273525A1 (en) 2018-09-27
EA201890826A1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
EA201790657A8 (ru) Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы
MY197720A (en) Bicyclic heterocycles as fgfr inhibitors
BR112019005969A2 (pt) inibidores seletivos de jak1 inovadores e usos dos mesmos
CY1120415T1 (el) Θεραπευτικα δραστικα παραγωγα πυραζολο-πυριμιδινης
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
IN2015DN03751A (pt)
HK1247923A1 (zh) 可用作哺乳動物酪氨酸激酶ror1活性抑制劑的2-苯基-3h-咪唑並[4，5-b]吡啶衍生物
PH12016501349A1 (en) Hydroxy formamide derivatives and their use
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
PH12017500342A1 (en) 7 - (morpholinyl) -2- (n-piperazinyl) methyl thieno [2,3-c] pyridine derivatives as anticancer drugs
BR112016013007A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
BR112018006138A2 (pt) derivados de piridina fundidos como inibidores da cinase
BR112018011656A2 (pt) derivados de hexahidropirzinotriazinona como inibidores de quinase
EP3676256A4 (en) NOVEL BARBITURIC ACID DERIVATIVES, THEIR PRODUCTION AND USE THEREOF AS LEUCOCYTE TRANSMIGRATION INHIBITORS AND FOR THE TREATMENT OF INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER
CO2019014026A2 (es) Formas cristalinas de seletalisib

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired